Eltrombopag – May 2022

Eltrombopag and Romiplostim: eltrombopag: Tablet 25 mg (as olamine), Tablet 50 mg (as olamine); romiplostim: Powder for injection 375 micrograms, Powder for injection 625 micrograms; Revolade® and Nplate® – May 2022

Brand names:
- Revolade®
Pharmaceutical Company:
- Novartis Pharmaceuticals Australia Pty Limited
Condition/Indication: Thrombopoietin receptor agonists (TPO-RAs) for primary immune thrombocytopenia (ITP)
Meeting Date: May 2022
Public Summary Document (PSD) May 2022 PBAC Meeting - (PDF 440KB)
Public Summary Document (PSD) May 2022 PBAC Meeting - (Word 56KB)

Related Public Summary Documents

Romiplostim – May 2022

Last updated

26 August 2022